Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Chiron Corporation |
---|---|
Information provided by: | Chiron Corporation |
ClinicalTrials.gov Identifier: | NCT00045877 |
The purpose of this study is to determine the safety and effectiveness of combination therapy with Proleukin and Rituxan on patients with low-grade Non-Hodgkin's Lymphoma who have previously failed Rituxan treatments.
Condition | Intervention | Phase |
---|---|---|
Lymphoma, Non-Hodgkin |
Drug: Recombinant Human Interleukin-2 and Rituximab |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Diagnosis and disease status:
Exclusion:
Study ID Numbers: | IL2NHL03 |
Study First Received: | September 12, 2002 |
Last Updated: | February 2, 2006 |
ClinicalTrials.gov Identifier: | NCT00045877 |
Health Authority: | United States: Food and Drug Administration |
Low-Grade or Follicular Non-Hodgkin's Lymphoma |
Lymphatic Diseases Aldesleukin Immunoproliferative Disorders Interleukin-2 Rituximab Lymphoma, small cleaved-cell, diffuse |
Lymphoma, Follicular Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma Follicular lymphoma |
Anti-Infective Agents Neoplasms by Histologic Type Anti-HIV Agents Immune System Diseases Antineoplastic Agents Physiological Effects of Drugs Antiviral Agents Pharmacologic Actions |
Neoplasms Anti-Retroviral Agents Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Analgesics Peripheral Nervous System Agents Central Nervous System Agents |